The histamine H 4 receptor is a novel G-protein-coupled receptor with a unique pharmacological profile. The distribution of H 4 mRNA suggests that it may play a role in the regulation of immune function, particularly with respect to allergy and asthma. To define the histamine-binding site of this receptor, molecular modeling and site-directed mutagenesis were used to predict and alter amino acids residing in the histaminebinding pocket. The effects of these alterations on histamine binding and receptor activation were then assessed. (6.52) in TM6 play a role in receptor activation but are not involved in histamine binding. Taken together, these data indicate that although histamine seems to bind to the H 4 receptor in a fashion similar to that predicted for the other histamine receptor subtypes, there are also important differences that can probably be exploited for the discovery of novel H 4 -selective compounds.
with the N nitrogen atom of the histamine imidazole ring via an ion pair. In contrast, Thr 178 (5.42) and Ser 179 (5.43) in TM5 are not significantly involved in either histamine binding or receptor activation. These results resemble those for the analogous residues in the H 1 histamine receptor but contrast with findings regarding the H 2 histamine receptor. Our results also demonstrate that Asn 147 (4.57) in TM4 and Ser 320 (6.52) in TM6 play a role in receptor activation but are not involved in histamine binding. Taken together, these data indicate that although histamine seems to bind to the H 4 receptor in a fashion similar to that predicted for the other histamine receptor subtypes, there are also important differences that can probably be exploited for the discovery of novel H 4 -selective compounds.
Histamine is a biogenic amine that has tremendous influence over a variety of physiological and pathologic processes through different histamine receptors. Thus far, four pharmacologically distinct histamine receptors have been identified and cloned, all of which are members of the G-proteincoupled receptor family of proteins. Cloning of the first three histamine receptors, the H 1 , H 2 , and H 3 receptors, was reported previously (Gantz et al., 1991; Yamashita et al., 1991; Lovenberg et al., 1999) . Recently, the fourth histamine receptor, the H 4 receptor, was cloned independently by several groups (Oda et al., 2000; Liu et al., 2001; Morse et al., 2001; Nguyen et al., 2001; Zhu et al., 2001) . The H 4 receptor is preferentially expressed in tissues of immunological relevance, and its expression seems to be regulated by interleukin-10 or -13 (Morse et al., 2001) . Understanding the molecular mechanism for the interaction between histamine and the H 4 receptor will probably be useful for the development of selective H 4 antagonists and for elucidating and modulating its function in the future.
Site-directed mutagenesis studies were performed previously to investigate the molecular basis for binding of histamine and histaminergic antagonists to H 1 and H 2 receptors.
In transmembrane region (TM) 3, a conserved aspartic acid [amino acid position 107 (3.32) in human H 1 and position 98 (3.32) in human H 2 receptor] is essential for the binding of both histamine and basic antagonists for both receptors (Gantz et al., 1992; Ohta et al., 1994) . In the H 1 receptor, antagonists have been shown to vary in the strength of interaction with this aspartate (Nonaka et al., 1998) . In the H 3 receptor, TM3 residues adjacent to Asp 114 (3.32) have been shown to form the basis for species-specific binding of antagonists (Ligneaux et al., 2000; Lovenberg et al., 2000) . Residues in TM5 of the guinea pig H 1 and human H 2 receptors have also been shown to be required for histamine binding (Gantz et al., 1992; Leurs et al., 1994) . Asn 207 (5.46) in TM5 of the H 1 receptor is involved in hydrogen binding with the N nitrogen atom of histamine, whereas Asp 186 (5.42) in TM5 of the H 2 receptor is connected to the same N nitrogen atom of histamine by an ion pair (Gantz et al., 1992; Leurs et al., 1994) . In addition, Thr 190 (5.46) in TM5 of the H 2 receptor was shown to be important in establishing the kinetics of histamine binding and action (Gantz et al., 1992) . This residue is thought to participate in hydrogen binding to the N histamine nitrogens participate in binding and receptor activation (Weinstein et al., 1976) .
In this study, we carried out computer modeling of the H 4 receptor based on its primary sequence and examined the putative histamine-binding pocket. (Fig. 1) . The bulkier side chains at these positions in the H 1 , H 2 , and H 3 receptors have the potential to impede access of histamine to the binding pocket. The molecular model would predict that the difference in the identities of the residues at these two sites between H 4 and the other three described histamine receptors have potential implications for subtype-specific differences in histamine interaction.
To explore the hypotheses regarding the importance of the residues mentioned above for H 4 receptor binding and activation by histamine, we mutated these residues individually and in combination. The ability of each mutant and the wild-type receptor to bind and respond to histamine was measured. The results suggest a model for subtype-specific differences in the mechanism of interaction between histamine and its receptor.
Materials and Methods
Modeling of the Histamine H 4 Receptor. A molecular model of the human H 4 receptor was constructed from the structure of rhodopsin (Palczewski et al., 2000) , using a method described previously for modeling the human melanin-concentrating hormone receptor (MacDonald et al., 2000) . Briefly, the model was built with the Look program (Molecular Application Group, Palo Alto, CA), which uses the SEGMED program (Levitt, 1992) . A model of histamine was docked to the H 4 receptor homology model at a site corresponding to its expected binding pocket in H 1 and H 2 receptors, based on prior mutagenesis data. The resulting complex model was refined by 1000 steps of molecular mechanics minimization with the Insight II/Discover program (Accelrys, San Diego, CA).
Site-Directed Mutagenesis. The human H 4 receptor cDNA (Morse et al., 2001 ) was subcloned into the Nhe-1 and Not-1 sites of the mammalian expression vector pME18-CD8-Flag, which allows an expressed protein to be epitope-tagged with N-terminal FLAG peptide and includes a signal peptide sequence derived from CD8 that promotes efficient expression. All the point mutations were introduced using a QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The full-length wild-type and mutant cDNA sequences were verified using the cycle-sequencing method with the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA).
Cell Culture, Transfection, and Expression. Serum-free medium-adapted (SFM) HEK-293 F cells (Invitrogen, Carlsbad, CA) were grown at 37°C in a humidified atmosphere with 5% CO 2 in Dulbecco's modified Eagle's medium containing 10% (v/v) fetal bovine serum. Cells were transiently transfected with the wild-type or mutant H 4 receptor cDNA in pME18-CD8-Flag using LipofectAMINE 2000 reagent (Invitrogen). Receptor expression on the cell surface was determined by flow cytometric analysis using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). Briefly, cells were harvested in 5 mM ice-cold EDTA in PBS 24 h after transfection, washed twice with PBS, and stained with biotinylated anti-FLAG M 2 monoclonal antibody (Sigma-Aldrich, St. Louis, MO) on ice for 30 min. After being washed twice with PBS, the cells were then stained with phycoerythrin-conjugated streptavidin (PharMingen, San Diego, CA) for 30 min on ice, followed by two washes with cold PBS before being analyzed.
Membrane Preparation. Twenty-four hours after transfection, the cells were harvested in 50 mM ice-cold Tris-HCl, pH 7.5, and homogenized with a homogenizer (setting 2, 30 s; Polytron; Brinkmann Instruments, Westbury, NY). The homogenate was centrifuged for 5 min at 1,000g to remove nuclei and unbroken cells. The supernatant was centrifuged at 50,000g for 10 min, and the resulting pellet was resuspended in 50 mM ice-cold Tris-HCl, pH 7.5. The protein concentration of the membrane preparation was measured by using BCA Assay Reagent (Pierce Chemical, Rockford, IL).
Histamine H 4 Receptor-Binding Studies. For saturation binding, membrane proteins (40-60 g) were incubated in a total volume of 200 l of 50 mM Tris-HCl, pH 7.5, with a range of [ 3 H]histamine dihydrochloride (Amersham Biosciences, Piscataway, NJ) concentrations for 1 h at 30°C. Nonspecific binding was determined by inclusion of 1 mM histamine. The bound radioactivity was separated by filtration through polyethyleneimine-treated GF/B filters (Packard BioScience, Meriden, CT) with a Filtermate 196 harvester (Packard BioScience). The filters were washed eight times with 50 mM ice-cold Tris-HCl, pH 7.5, and radioactivity retained on the filters was measured by liquid scintillation counting with a TopCount (Packard BioScience) at 34% efficiency. All experiments were performed in triplicate. The binding data were evaluated with Prism (GraphPad Software, San Diego, CA) and analyzed for one-and two-site fits. A single-binding-site model best described all curves. Ca 2؉ Mobilization Assay. HEK-293 SFM cells were transiently cotransfected overnight in DMEM and 10% FCS with the wild-type or mutant H 4 receptor cDNAs in pME18-CD8-Flag (0.5 g/cm 2 ) and the chimeric G␣ q/i protein cDNA in pCDNA 3 (0.05 g/cm 2 ) (Morse et al., 2001) using LipofectAMINE 2000 reagent (1.5 l/cm 2 ). Twentyfour hours after transfection, the cells were harvested and reseeded at 5 ϫ 10 5 cells/well in DMEM and 10% FCS in the poly(D-lysine)-treated, 96-well, clear-bottomed black plates (BD Biosciences). Forty-eight hours after transfection, the cells were loaded for 1 h with 4 M Fluo-3AM (Molecular Probes, Eugene, OR) in loading buffer Fig. 1 . Alignment of amino acid sequences of the third, fourth, fifth, and sixth transmembrane domain in human histamine H 1 , H 2 , H 3 , and H 4 receptors. The bold and underlined residues in the H 4 receptor are predicated to be involved in the action of histamine. These residues are also numbered using the Ballesteros and Weinstein index system modified by van Rhee and Jacobson (Ballesteros and Weinstein, 1995; van Rhee and Jacobson, 1996) .
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at ASPET Journals on April 15, 2017 molpharm.aspetjournals.org (10% FCS and 20 mM HEPES in DMEM). After being washed extensively with washing buffer (Hanks' balanced salt solution and 20 mM HEPES, pH 7.4) to remove excess dye, the cells were evaluated for agonist-induced intracellular mobilization using a Fluorescent Imaging Plate Reader (Molecular Devices, Menlo Park, CA).
Results

Prediction of Histamine H 4 Receptor Interaction
Based on Receptor Modeling. The initial model of histamine docked into the hypothetical binding site in the H 4 receptor is shown in Fig. 2 . Histamine is predicted to bind in a pocket formed by residues in TM3 through TM6, anchored by an ion pair between the side chain of Investigation of the Histamine-Binding Site by SiteSpecific Mutagenesis. To experimentally explore the interaction of histamine with the amino acids of the H 4 receptor that our model predicted would be important, these residues were mutated individually or in combination (see Table 1 for the list of mutants). During the process of subcloning the wild-type H 4 receptor cDNA into a mammalian expression vector, we introduced a FLAG epitope at the N terminus of the receptor to facilitate examination of cell-surface expression. This construct was subsequently used to generate the mutant receptors used in this study. Transfection of the FLAG-H 4 receptor in HEK-293 SFM cells resulted in the appearance of cell-surface FLAG staining and high-affinity binding sites for [
3 H]histamine, with a K D of 15.3 nM ( Fig. 3 ; Table 1 ). The K D of the FLAG-H 4 receptor obtained in this study agrees with that reported previously for the H 4 receptor without the FLAG epitope (Oda et al., 2000; Morse et al., 2001; Zhu et al., 2001) . This indicates that a FLAG epitope at the N terminus of the H 4 receptor does not affect histamine binding.
Among the biogenic amine and some peptide G-proteincoupled receptors, a conserved Asp in TM3 has been shown to be critical for interaction with their natural agonists (for discussion see MacDonald et al., 2000 3 H]histamine binding was not caused by a lack of receptor cell-surface expression, because analysis of cell-surface FLAG staining revealed that the wild-type and the three mutant H 4 receptors were expressed on the cell surface at a comparable level (Fig. 4) and Ser 320 (6.52) in TM6 of the H 4 receptor were located near the histamine-binding pocket. Increasing the side-chain volume of the residues at these two positions could conceivably affect histamine binding. To investigate whether the amino acids at these two positions play a role in histamine binding to the H 4 receptor, Asn 147 (4.57) was mutated to Ala or Tyr and Ser 320 (6.52) was mutated to Ala or Phe. All four resulting mutant receptors were expressed on the cell surface at a level similar to the wild-type receptor (Fig. 4) (Morse et al., 2001 ). In dose-response studies, cells expressing both the wild-type H 4 receptor with the N-terminal FLAG epitope and G␣ q/i exhibited Ca 2ϩ mobilization in response to histamine treatment. The histamine dose for half-maximal response (EC 50 ) (21 Ϯ 0.6 nM) was similar to those published previously (Oda et al., 2000; Morse et al., 2001) (4.57) and Ser 320 (6.52) did not seem to contribute strongly to histamine binding but did seem to affect histamine signaling, we investigated the ability of other H 4 agonists to activate the Asn 147 (4.57) 3 Tyr and Ser 320 (6.52) 3 Phe mutant receptors. In general, the mutant receptors responded similarly to the histamine derivatives (R)-(Ϫ)-␣-methylhistamine, (S)-(ϩ)-␣-methylhistamine, imetit, and imepip, compared with histamine itself (Table 2 ; Fig. 7) . Thus, the maximum response was reduced for all compounds at the Asn 147 (4.57) 3 Tyr mutant compared with the wild type, although R-(Ϫ)-␣-methylhistamine was least affected. The EC 50 values for the agonists were reduced as well, with the exception of S-(ϩ)-␣-methylhistamine, which exhibited somewhat higher potency at the mutant receptor compared with the wild type ( Table 2 ). For the Ser 320 (6.52) 3 Phe mutation, all compounds exhibited higher maximal responses, whereas the potency of all the compounds was reduced compared with the wild type ( Table 2 ). This mutation, however, had the greatest effect on the action of histamine compared with the other compounds.
Discussion
Recently, a fourth member of the histamine family of Gprotein-coupled receptors has been identified and characterized by several groups. The H 4 histamine receptor exhibits the highest degree of similarity to the H 3 histamine receptor, and comparison of the sequences of the four histamine receptors reveals that a number of amino acids that have been implicated in histamine binding to the other receptor subtypes are conserved in the H 4 receptor. To begin to delineate the histamine-binding site on the H 4 receptor, molecular modeling and site-directed mutagenesis were carried out to determine the involvement of specific amino acid residues in histamine binding and receptor activation. Previous mutagenesis studies on the H 1 and H 2 receptors (Gantz et al., 1992; Ohta et al., 1994) , the ␣ and ␤ adrenergic receptors (Strader et al., 1987; Strader et al., 1988; Wang et al., 1991) , and the M1 muscarinic acetylcholine receptor Fraser et al., 1989) 
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Other residues in TM5 have also been shown to be involved in the binding of histamine and other biogenic amines to their receptors. In the ␤ 2 adrenergic receptor, two Ser residues in TM5, corresponding to Ser 179 (5.43) and Glu 182 (5.46) in the H 4 receptor, have been shown to be involved in hydrogen bonding to the meta-and para-hydroxyl groups of the catechol ring of epinephrine (Strader et al., 1989a) . In the ␣ 1 -adrenergic receptor, Ser 188 (5.42) is critical for binding to the meta-hydroxyl of the endogenous agonists (Hwa and Perez, 1996) . Likewise, in the D1 dopamine receptor, mutation of either Ser 198 (5.42) or Ser 199 (5.43) to Ala disrupts agonist binding (Pollock et al., 1992) . In the dopamine D2 receptor, Ser 193 (5.42) contributes notably to the binding of dopamine and Ser 194 (5.43) is absolutely required for activation of agonists as a result of bonding with the -hydroxyl group of catecholamines (Cox et al., 1992) . For serotonin receptors, Ser 5.43 of the human 5-HT 4 was proposed to interact with serotonin through a hydrogen bond (Mialet et al., 2000) ; and mutation of the analogous Ser 5.43 in the rat 5-HT 2A receptor to alanine caused a 6-fold decrease in 5-HT binding affinity (Shapiro et al., 2000) . In the 5-HT 1A receptor, substitution of Ser 198 (5.42) or Thr 199 (5.43) with alanine resulted in a significant reduction of serotonin binding (Ho et al., 1992) . The analogous residue in the rat M 3 muscarinic receptor, Thr 234 (5.42), also affects acetylcholine binding affinity and the ability of the receptor to stimulate agonistdependent phosphatidylinositol hydrolysis (West et al., 1992) . Taken together, these studies clearly demonstrate the conservation of the critical role of TM5 Ser and/or Thr residues in biogenic amine binding. In the case of histamine receptors, however, this role is not as well conserved. Although Thr 190 (5.46) in TM5 of the H 2 histamine receptor has been proposed to interact with the N nitrogen of the histamine imidazole ring by a hydrogen bond and seems important for establishing the kinetics of histamine binding and activation (Gantz et al., 1992) , the homologous TM5 Thr (5.42) of the human and guinea pig H 1 receptors (Thr 174 and Thr 203 , respectively) are not required for histamine binding (Leurs et al., 1994; Ohta et al., 1994 (Gantz et al., 1992) . 
The computer modeling studies of the H 4 receptor also revealed two additional amino acid residues, Asn 147 (4.57) and Ser 320 (6.52), that were predicted to be in positions that could allow interaction with histamine in the predicted binding pocket. Comparison with the analogous residues in other biogenic amine receptors reveals that Asn 147 (4.57) in TM4 of the H 4 receptor is unique; this position is occupied by Trp, Phe, or Tyr in the H 1 , H 2 , and H 3 receptors, respectively. In TM6, the position occupied by Ser 320 (6.52) in the H 4 receptor is generally found to be Phe in other biogenic amine receptors, except for the H 3 receptor, which has Thr at this position. In the ␤ 2 adrenergic receptor, the Phe at the corresponding position (6.52) was suggested to be involved in forming an aromatic-aromatic interaction with the catecholamine phenyl ring of norepinephrine and important for the receptor agonist binding (Strader et al., 1989b) . The adjacent Phe (6.51) in the ␣ 1B adrenergic receptor was found to be necessary not only for agonist binding but also for agonist potency and efficacy (Chen et al., 1999 (Mialet et al., 2000) . This conclusion contrasts with our model, which suggests that increased side-chain volume at these two sites could impede histamine binding to the H 4 receptor. However, both Asn 147 (4.57) and Ser 320 (6.52) of the H 4 receptor seem to be involved in activation of the H 4 receptor by histamine. Replacing Asn 147 (4.57) of the H 4 receptor with Tyr to mimic the H 3 receptor seems to be detrimental to histamine signaling through the H 4 receptor, as evidenced by a reduction of 50% in the ability of the receptor to respond to histamine with no change in levels of receptor expression. In contrast, changing Ser 320 (6.52) of the H 4 receptor to Phe to imitate the H 1 , H 2 , and other biogenic amine receptors had the unexpected effect of greatly reducing the potency of histamine while at the same time doubling the maximal response of the receptor to histamine treatment. Although the increased efficacy could be due to an increase in receptor expression, paradoxically, this receptor mutant exhibited a reduction in maximal [ 3 H]histamine binding (and a slight change in affinity) that did not seem to be correlated with reduced surface expression as assessed by anti-FLAG antibody staining.
The altered signaling of the Asn 147 (4.57) 3 Tyr and Ser 320 (6.52) 3 Phe receptors was not specific for histamine. Examination of the response to several histamine analogs generally revealed the same pattern of activity at both mutant receptors as seen with histamine, albeit to differing extents. Thus, although the maximal responses for all compounds were reduced at the Asn 147 (4.57) 3 Tyr mutant, this mutation had the smallest effect on R-(Ϫ)-␣Ϫmethylhistamine and the greatest effect on imepip. On the other hand, mutation of Ser 320 (6.52) 3 Phe resulted in decreased potency and increased efficacy for all compounds, although the effects were greatest for histamine.
The observed reduction in maximal [ 3 H]histamine binding and histamine potency at the Ser 320 (6.52) mutant might be explained by altered interactions with G-proteins leading to an increase in the proportion of low-affinity histamine-binding states, which may not be detected with the ligand and conditions used in the present study. To fully address this issue, however, the development of an H 4 receptor antagonist radioligand will be required. In any case, the H 4 receptor clearly differs from the H 1 and H 2 receptors in the required chemical or physical nature of residue position 6.52.
Previous studies on rhodopsin and ␤ 2 adrenergic receptor have suggested that a critical step in agonist-induced activation of G-protein-coupled receptors is the movement of TM6 and its cytoplasmic extension, which is important for Gprotein coupling. For example, photoactivation of rhodopsin involves rotation and tilting of TM6 relative to TM3 (Farrens et al., 1996; Lin and Sakmar, 1996; Dunham and Farrens, 1999) . It has been similarly suggested that TM6 of the ␤ 2 adrenergic receptor would move in response to agonist stimulation (Javitch et al., 1997; Jensen et al., 2001) . Recently, the movement of TM6 after agonist activation of the ␤ 2 adrenergic receptor was investigated by fluorescence spectroscopy, and the results suggested clockwise rotation of TM6 and/or tilting of the cytoplasmic end of TM6 toward TM5 (Ghanouni et al., 2001) .
Specific residues in TM6 have been suggested to be involved in the movement of this TM region upon agonist activation. Grånä s et al. (1998) have suggested that Phe 331 (6.52) in the 5HT 1B receptor, analogous to Ser 320 (6.52) in the H 4 receptor, is involved in the conformational changes associated with signal transduction. In the ␣ 1B adrenergic receptor, a highly conserved Phe 303 (6.44) in TM6 has been postulated to be a key residue in coupling TM6 movement to G-protein activation (Chen et al., 2000 (Chen et al., , 2002 . It remains unclear whether the demonstrated effects of the mutations at the H 4 Ser 320 (6.52) are due to nonspecific global or local changes in the receptor structure or disruption of particular intramolecular interactions that serve to regulate the ability of histamine to promote H 4 receptor signal transduction. Given the findings mentioned above, which suggest that agonist-induced TM6 movement for G-protein coupling critically depends on the identity of individual residues in TM6, it is possible that Ser 320 (6.52) in the histamine H 4 receptor is involved TM6 movement and subsequent G-protein coupling on histamine activation. This hypothesis is currently under further investigation.
Taken together, the unique way histamine interacts with residues in the binding pocket of the H4 receptor offers potential for the development of subtype-selective antagonists. These are likely to provide further insights into the physiological role of this newly discovered histamine receptor subtype.
